Urispas, Omhulde Tabletten

Uses

Urispas, Omhulde Tabletten is used for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis and urethrocystitis.

Urispas, Omhulde Tabletten is also used to associated treatment for these conditions: Cystitis, Dysuria, Kidney Stones, Menstrual Distress (Dysmenorrhea), Neurogenic Bladder Dysfunction, Nocturia, Pelvic Floor Dysfunctions, Pelvic Pain, Prostatitis, Suprapubic pain, Urethritis, Urethrotrigonitis, Urinary Incontinence (UI), Urinary Tract Infection, Urinary Urgency, Uterine dyskinesia, Cystalgia, Urethrocystitis

How Urispas, Omhulde Tabletten works

Urispas, Omhulde Tabletten acts as a direct antagonist at muscarinic acetylcholine receptors in cholinergically innervated organs. Its anticholinergic-parasympatholytic action reduces the tonus of smooth muscle in the bladder, effectively reducing the number of required voids, urge incontinence episodes, urge severity and improving retention, facilitating increased volume per void.

Dosage

Urispas, Omhulde Tabletten dosage

Adults and children over 12 years of age: 100 mg to 200 mg 3 times a day. With improvement of symptoms, the dose may be reduced.

Pediatric Use: Safety and effectiveness in children below the age of 12 years have not been established.

Side Effects

Gastrointestinal: Nausea, vomiting, dry mouth.

CNS: Vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness.

Hematologic: Leukopenia (which is reversible upon discontinuation of the drug).

Cardiovascular: Tachycardia and palpitation.

Allergic: Urticaria and other dermatoses, eosinophilia and hyperpyrexia.

Ophthalmic: Increased ocular tension, blurred vision, disturbance in eye accommodation.

Toxicity

The oral LD50 for flavoxate HCl in rats is 4273 mg/kg. The oral LD50 for flavoxate HCl in mice is 1837 mg/kg. Symptoms of overdose include convulsions, decreased ability to sweat, (warm, red skin, dry mouth, and increased body temperature), hallucinations, increased heart rate and blood pressure, and mental confusion.

Precaution

Urispas, Omhulde Tabletten should be given cautiously in patients with suspected glaucoma

Food Interaction

• Take with or without food. The absorption is unaffected by food.

[Moderate] GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.

Use in combination may result in additive central nervous system depression and
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.

Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

Urispas, Omhulde Tabletten Drug Interaction

Moderate: tramadol, tramadolMinor: acetaminophen, acetaminophen, acetaminophen, acetaminophenUnknown: ginkgo, ginkgo, phenazopyridine, phenazopyridine, levothyroxine, levothyroxine, cyanocobalamin, cyanocobalamin, ascorbic acid, ascorbic acid, ergocalciferol, ergocalciferol, cholecalciferol, cholecalciferol

Urispas, Omhulde Tabletten Disease Interaction

Major: GI/urinary obstructionModerate: angle-closure glaucoma

Elimination Route

Well absorbed from gastrointestinal tract.

Elimination Route

57% of the flavoxate HCl was excreted in the urine within 24 hours.

Pregnancy & Breastfeeding use

Pregnancy: Pregnancy Category B. This drug should be used during pregnancy only if clearly needed.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Caution should be exercised when flavoxate is administered to a nursing woman.

Contraindication

Urispas, Omhulde Tabletten is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.

Storage Condition

Store Urispas, Omhulde Tabletten at room temperature, between 20 and 25 degrees C

Innovators Monograph

You find simplified version here Urispas, Omhulde Tabletten